{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:48:59Z","timestamp":1781840939721,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd009072.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T00:00:00Z","timestamp":1501372800000}}],"reference-count":143,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T00:00:00Z","timestamp":1501372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T00:00:00Z","timestamp":1501372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009072.pub3","type":"journal-article","created":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T08:51:36Z","timestamp":1501404696000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathogen-reduced platelets for the prevention of bleeding"],"prefix":"10.1002","volume":"2017","author":[{"given":"Lise J","family":"Estcourt","sequence":"first","affiliation":[{"name":"NHS Blood and Transplant; Haematology\/Transfusion Medicine; Level 2, John Radcliffe Hospital Headington Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Malouf","sequence":"additional","affiliation":[{"name":"University of Oxford; National Perinatal Epidemiology Unit (NPEU); Old Road Campus Oxford UK OX3 7LF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University of Oxford; Oxford Clinical Trials Research Unit; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Windmill Road Oxford Oxfordshire UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; John Radcliffe Hospital Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Stanworth","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust and University of Oxford; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital, Headley Way Headington Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F","family":"Murphy","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust and University of Oxford; NHS Blood and Transplant; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital Headington Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,30]]},"reference":[{"issue":"9s","key":"10.1002\/14651858.CD009072.pub3-BIB0001|cit1","first-page":"117A. Abstract","article-title":"Clinical study in pediatric hemato-oncology patients: efficacy of pathogen inactivated buffy coat platelets versus aphaeresis platelets","volume":"46","author":"Agliastro","year":"2006","journal-title":"Transfusion"},{"issue":"12","key":"10.1002\/14651858.CD009072.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/j.1537-2995.2009.02347.x","article-title":"Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates","volume":"49","author":"Ambruso","year":"2009","journal-title":"Transfusion"},{"issue":"Suppl","key":"10.1002\/14651858.CD009072.pub3-BIB0003|cit3","first-page":"20A. Abstract N","article-title":"Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients","volume":"48","author":"Goodrich","year":"2008","journal-title":"Transfusion"},{"issue":"11","key":"10.1002\/14651858.CD009072.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1537-2995.2010.02694.x","article-title":"A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology","volume":"50","author":"Mirasol Clinical Evaluation Study Group","year":"2010","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0005|cit5","unstructured":"NCT00263809 Safety and performance of MIRASOL\u00ae PRT treated platelet transfusion products clinicaltrials.gov\/ct2\/show\/NCT00263809"},{"issue":"s1","key":"10.1002\/14651858.CD009072.pub3-BIB0006|cit6","first-page":"17A. Abstract N","article-title":"Clinical trial on the use of pathogen inactivated platelets, with Helinx\u00ae technology, in cardio paediatric surgery and cirrhotic patients","volume":"44","author":"Francisci","year":"2004","journal-title":"Transfusion"},{"issue":"9","key":"10.1002\/14651858.CD009072.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1537-2995.2005.00550.x","article-title":"Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set","volume":"45","author":"Janetzko","year":"2005","journal-title":"Transfusion"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009072.pub3-BIB0008|cit8","first-page":"67A. Abstract N","article-title":"TEG as a surrogate marker for the haemostatic function of PRT treated platelets in thrombocytopenic patients","volume":"52","author":"Johansson","year":"2012","journal-title":"Transfusion"},{"issue":"9","key":"10.1002\/14651858.CD009072.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/trf.12055","article-title":"A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia","volume":"53","author":"Johansson","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0010|cit10","unstructured":"NCT01368211 Mirasol-treated platelets - (Pathogen Reduction Extended Storage Study) (PRESS) clinicaltrials.gov\/ct2\/show\/NCT01368211"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0011|cit11","unstructured":"ISRCTN88278819 Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in haemato-oncological patients www.isrctn.com\/ISRCTN88278819"},{"issue":"2","key":"10.1002\/14651858.CD009072.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","article-title":"Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction","volume":"150","author":"Kerkhoffs","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"s3","key":"10.1002\/14651858.CD009072.pub3-BIB0013|cit13","first-page":"2A. Abstract No","article-title":"Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients","volume":"49","author":"Kerkhoffs","year":"2009","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0014|cit14","unstructured":"NTR861 Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in hemato-oncological patients www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=861"},{"issue":"3","key":"10.1002\/14651858.CD009072.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","article-title":"A multi-center study of therapeutic efficacy and safety of platelet components treated with amotosalen and UVA pathogen inactivation stored for 6 or 7 days prior to transfusion","volume":"153","author":"Lozano","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0016|cit16","unstructured":"NCT00261924 Efficacy and safety study of platelets treated for pathogen inactivation and stored for up to seven days (TESSI) www.clinicaltrials.gov\/ct2\/show\/NCT00261924"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0017|cit17","unstructured":"Benjamin RJ Goodnough LT Lopez-Perez I Strauss R McCullough J Slichter S Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments. However fresh platelets result in superior hemostasis: results of the SPRINT trial Transfusion 2003 9A. Abstract No. S29-030E"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0018|cit18","unstructured":"Conlan MGC Vesole DH Staudtmauer E Goodnough LT Coutre S Howard FD Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation: results of the phase III SPRINT trial of Intercept platelets Vox Sanguinis 2005 36-7. Abstract No. 5P-035"},{"issue":"s2","key":"10.1002\/14651858.CD009072.pub3-BIB0019|cit19","first-page":"28A. Abstract N","article-title":"Serious pulmonary adverse events and acute lung injury following repeated platelet transfusions","volume":"48","author":"Corash","year":"2008","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0020|cit20","unstructured":"Corash L Lin JS Eiden J Acute lung injury in patients receiving repeated platelet transfusions Vox Sanguinis 2008 300-1. Abstract No. P-662"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Corash L Lin JS Sherman CD Eiden J Determination of acute lung injury following repeated platelet transfusions Blood 2010 1014 20","DOI":"10.1182\/blood-2010-06-293399"},{"issue":"9s","key":"10.1002\/14651858.CD009072.pub3-BIB0022|cit22","first-page":"17S. Abstract N","article-title":"A platelet transfusion threshold of 20 x 109\/L compared to 10 x 109\/L is associated with increased pre-transfusion bleeding and increased platelet transfusions: results of the SPRINT study","volume":"42","author":"Goodnough","year":"2002","journal-title":"Transfusion"},{"issue":"11","key":"10.1002\/14651858.CD009072.pub3-BIB0023|cit23","first-page":"450a. Abstract","article-title":"Pathogen inactivated platelets using Helinx (TM) technology (INTERCEPT) are hemostatically effective in thrombocytopenic patients: the SPRINT trial","volume":"98","author":"McCullough","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD009072.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"issue":"109","key":"10.1002\/14651858.CD009072.pub3-BIB0025|cit25","first-page":"Abstract No. 32","article-title":"INTERCEPT platelets are hemostatically as effective as conventional platelets in the prophylaxis and treatment of bleeding: results of the SPRINT trial","volume":"83","author":"Murphy","year":"2002","journal-title":"Vox Sanguinis"},{"issue":"11 Pt 2","key":"10.1002\/14651858.CD009072.pub3-BIB0026|cit26","first-page":"815a. Abstract","article-title":"Transfusion of INTERCEPT platelets vs. reference platelets at doses >\/=3.0x1011 results in comparable hemostasis and platelet and RBC transfusion requirements. Results of the SPRINT trial","volume":"102","author":"Murphy","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD009072.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1537-2995.2005.00671.x","article-title":"Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light","volume":"46","author":"Murphy","year":"2006","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1537-2995.2006.00761.x","article-title":"Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial","volume":"46","author":"Pineda","year":"2006","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0029|cit29","unstructured":"Slichter SJ Murphy S Buchholz D Lin J Corash L Conlan M INTERCEPT platelets (plts) and conventional plts provide comparable hemostatic responses in thrombocytopenic patients: the SPRINT trial Blood 2002 141b. Abstract No. 4048"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Snyder E McCullough J Slichter SJ Strauss RG Lopez-Plaza I Lin JS Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial Transfusion 2005 1864 75","DOI":"10.1111\/j.1537-2995.2005.00639.x"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0031|cit31","unstructured":"Strauss RG Eastlund DT Lopez-Plaza I Lin JS Conlan MG INTERCEPT platelets provided effective hemostasis in thrombocytopenic children: Results of the SPRINT trial Pediatric Research 2003 287A. Abstract No. 1635"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0032|cit32","first-page":"Abstract No. 62","article-title":"Intercept platelets exhibit immunologic refractoriness comparable to conventional platelets","volume":"89","author":"Strauss","year":"2004","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Vesole D Stadtmauer E Goodnough LT Coutre S Howard F Lin JS Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the Phase III SPRINT trial of INTERCEPT pathogen inactivated platelets Biology of Blood and Bone Marrow Transplantation 2004 233","DOI":"10.1016\/j.bbmt.2003.12.166"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0034|cit34","unstructured":"NCT01642563 Italian Platelet Technology Assessment Study (IPTAS) www.clinicaltrials.gov\/ct2\/show\/NCT01642563"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"Abstract No. LE","DOI":"10.2450\/2009.0013-09","article-title":"Pathogen inactivated platelets and prevention of immunological adverse reactions: the Italian Platelet Technology Assessment Study (IPTAS)","volume":"7, Suppl 1","author":"Rebulla","year":"2009","journal-title":"Blood Transfusion"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009072.pub3-BIB0036|cit36","first-page":"3A. Abstract no","article-title":"Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies","volume":"55","author":"Rebulla","year":"2015","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD009072.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1537-2995.2006.00739.x","article-title":"Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study","volume":"46","author":"Simonsen","year":"2006","journal-title":"Transfusion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0038|cit38","first-page":"Abstract No. O1","article-title":"Hemostatic function of photo-chemically treated (PCT) platelets (PLTS) in thrombocytopenic patients","volume":"79","author":"Slichter","year":"2000","journal-title":"Vox Sanguinis"},{"issue":"5","key":"10.1002\/14651858.CD009072.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1537-2995.2006.00791.x","article-title":"Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct bleeding times in patients with thrombocytopenia","volume":"46","author":"Slichter","year":"2006","journal-title":"Transfusion"},{"issue":"4 Suppl 11","key":"10.1002\/14651858.CD009072.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0037-1963(01)90123-4","article-title":"Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology","volume":"38","author":"Cazenave","year":"2001","journal-title":"Seminars in Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0041|cit41","first-page":"132s. Abstract","article-title":"INTERCEPT buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: the EUROSPRITE trial","volume":"8","author":"Cazenave","year":"2001","journal-title":"Transfusion Clinique et Biologique"},{"issue":"Suppl","key":"10.1002\/14651858.CD009072.pub3-BIB0042|cit42","first-page":"38S. Abstract N","article-title":"Platelets treated with HELINX\u2122 technology (HPC) are effective for multiple cycles of transfusion support of thrombocytopenia: the euroSPRITE trial","volume":"41","author":"Corash","year":"2001","journal-title":"Transfusion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0043|cit43","first-page":"Abstract No. 66","article-title":"Intercept platelet concentrates (IPC) are effective and safe for support of multiple cycles of thrombocytopenia: the EUROSPRITE Phase III Trial","volume":"86","author":"Corash","year":"2001","journal-title":"Haematologica"},{"issue":"110a","key":"10.1002\/14651858.CD009072.pub3-BIB0044|cit44","first-page":"Abstract No. 33","article-title":"Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets","volume":"83","author":"Kluter","year":"2002","journal-title":"Vox Sanguinis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0045|cit45","first-page":"100s. Abstract","article-title":"Results of the EUROSPRITE phase III trial: INTERCEPT buffy coat platelet concentrates (IPC) provide effective hemostasis for thrombocytopenic (TCP) patients (pts)","volume":"8","author":"Ljungman","year":"2001","journal-title":"Transfusion Clinique et Biologique"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0046|cit46","first-page":"100-1s. Abstrac","article-title":"The EUROSPRITE phase III trial of INTERCEPT buffy coat platelet concentrates (IPC) demonstrates IPC are safe when transfused to thrombocytopenic (TCP) patients (PTS)","volume":"8","author":"Pamphilon","year":"2001","journal-title":"Transfusion Clinique et Biologique"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009072.pub3-BIB0047|cit47","first-page":"100s, 133s. Abs","article-title":"Clinical refractoriness and HLA alloimmunisation are infrequent after multiple exposures to INTERCEPT-TM platelets","volume":"8","author":"Sintnicolaas","year":"2001","journal-title":"Transfusion Clinique et Biologique"},{"issue":"6","key":"10.1002\/14651858.CD009072.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial","volume":"101","author":"Rhenen","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD009072.pub3-BIB0049|cit49","first-page":"819a. Abstract","article-title":"S-59 (Helinx\u2122) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: results of the Eurosprite phase 3 trial","volume":"96","author":"Rhenen","year":"2000","journal-title":"Blood"},{"issue":"9s","key":"10.1002\/14651858.CD009072.pub3-BIB0050|cit50","first-page":"73S. Abstract N","article-title":"Prevention of HLA alloimmunization using UV-B irradiated platelet concentrates (PC): results of a prospective randomized clinical trial","volume":"33","author":"Andreu","year":"1993","journal-title":"Transfusion"},{"issue":"s1","key":"10.1002\/14651858.CD009072.pub3-BIB0051|cit51","first-page":"16A-7A. Abstrac","article-title":"Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction","volume":"44","author":"AuBuchon","year":"2004","journal-title":"Transfusion"},{"issue":"8","key":"10.1002\/14651858.CD009072.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1537-2995.2005.00202.x","article-title":"Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction","volume":"45","author":"AuBuchon","year":"2005","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0053|cit53","first-page":"130","article-title":"Clinical application of transfused platelet concentrates treated with Intercepttm blood system technology-experience from ufa center","volume":"107","author":"Ayupova","year":"2014","journal-title":"33rd International Congress of the International Society of Blood Transfusion, in Conjunction with the 33rd Congress of the KSBT and the 2014 Congress of the Korean Hematology Societies Seoul, South Korea"},{"issue":"1-2","key":"10.1002\/14651858.CD009072.pub3-BIB0054|cit54","first-page":"53","article-title":"Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates","volume":"39","author":"Berger","year":"2013","journal-title":"Onkologie"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1537-2995.1996.36496226140.x","article-title":"A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy","volume":"36","author":"Blundell","year":"1996","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"322-30","DOI":"10.1111\/j.1423-0410.2012.01614.x","article-title":"Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials","volume":"103","author":"Cid","year":"2012","journal-title":"Vox Sanguinis"},{"issue":"8","key":"10.1002\/14651858.CD009072.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1537-2995.2012.03951.x","article-title":"Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations","volume":"53","author":"Cook","year":"2013","journal-title":"Transfusion"},{"issue":"Suppl","key":"10.1002\/14651858.CD009072.pub3-BIB0058|cit58","first-page":"37S. Abstract N","article-title":"S-59 clearance and kinetics after transfusion of platelets treated with Helinx\u2122 technology","volume":"40","author":"Corash","year":"2000","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0059|cit59","unstructured":"Corash L Frequency of respiratory adverse events (AE) reported during active hemovigilance after transfusion of INTERCEPTTM Platelet Components (PC) AABB Annual Meeting and CTTXPO 2012; 2012 Oct 6-9; Boston, MA 2012"},{"issue":"7","key":"10.1002\/14651858.CD009072.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/trf.13026","article-title":"Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions","volume":"55","author":"Drawz","year":"2015","journal-title":"Transfusion"},{"issue":"s2","key":"10.1002\/14651858.CD009072.pub3-BIB0061|cit61","first-page":"1A-2A. Abstract","article-title":"A randomized controlled trial comparing autologous radiolabeled in vivo platelet recoveries and survivals of 7-day stored PRP and buffy coat platelets from the same donors","volume":"50","author":"Dumont","year":"2010","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD009072.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transci.2011.07.013","article-title":"Pathogen-inactivation of platelet components with the INTERCEPT Blood SystemTM: a cohort study","volume":"45","author":"Infanti","year":"2011","journal-title":"Transfusion and Apheresis Science"},{"issue":"8","key":"10.1002\/14651858.CD009072.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/trf.13038","article-title":"A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets","volume":"55","author":"MacLennan","year":"2015","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0064|cit64","first-page":"42","article-title":"Comparison of platelets stored for 2-5 vs 6-7 days in preventing and treating haemorrhage in thrombocytopenic patients - a randomised controlled trial","volume":"105","author":"MacLennan","year":"2013","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0065|cit65","unstructured":"NCT00742001 Feasibility study of Mirasol-treated whole blood red cell recovery and survival clinicaltrials.gov\/ct2\/show\/NCT00742001"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0066|cit66","unstructured":"NCT01615146 Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot clinicaltrials.gov\/ct2\/show\/NCT01615146"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0067|cit67","unstructured":"NCT02330081 Survival and recovery of radio-labeled platelets derived from Mirasol-treated whole blood (Medic) clinicaltrials.gov\/ct2\/show\/NCT02330081"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0068|cit68","unstructured":"NCT02653443 A randomized, multi-center, open-label, paired controlled, crossover in vivo study to assess the recovery and lifespan of radiolabeled autologous INTERCEPT treated apheresis platelet components suspended in nominal 35% plasma and 65% InterSol stored for 6 or 7 days clinicaltrials.gov\/ct2\/show\/NCT02653443"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0069|cit69","unstructured":"Rummler S Weinigel C Weise C Barz D Efficacy and safety of pathogen reduced plasma in plasma therapy in Germany AABB Annual Meeting and CTTXPO 2013; 2013 Oct 12-15; Denver, CO 2013"},{"issue":"81","key":"10.1002\/14651858.CD009072.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/j.1537-2995.2012.03959.x","article-title":"Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components","volume":"53","author":"Sigle","year":"2013","journal-title":"Transfusion"},{"issue":"26","key":"10.1002\/14651858.CD009072.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group","volume":"337","author":"TRAP Study Group","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1423-0410.2011.01555.x","article-title":"Meta-analysis of the studies of bleeding complications of platelet pathogen-reduced with the Intercept system","volume":"102","author":"Vamvakas","year":"2012","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0073|cit73","unstructured":"Phase III, randomised, double-blind, multi-centre clinical trial on clinical efficacy and safety of platelet concentrates treated with the THERAFLEX UV Platelets procedure in comparison to conventional platelet components (Capture) Ongoing study June 2016"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0074|cit74","unstructured":"NCT02783313 Pathogen Reduction Evaluation & Predictive Analytical Rating Score (PREPAReS) www.clinicaltrials.gov\/ct2\/show\/NCT02783313"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0075|cit75","unstructured":"NTR2106 The PREPAReS Study: Pathogen Reduction Evaluation & Predictive Analytical Rating Score www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=2106"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e010156","DOI":"10.1136\/bmjopen-2015-010156","article-title":"A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial","volume":"6","author":"Ypma","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0077|cit77","unstructured":"NCT01789762 Evaluation of the efficacy of platelets treated with pathogen inactivation process (EFFIPAP) www.clinicaltrials.gov\/ct2\/show\/NCT01789762"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0078|cit78","first-page":"23","article-title":"Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results","volume":"106","author":"Benjamin","year":"2014","journal-title":"International Society of Blood Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMp068178","article-title":"The continuing risk of transfusion-transmitted infections","volume":"355","author":"Blajchman","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0080|cit80","volume-title":"The 2014 Annual SHOT Report","author":"Bolton-Maggs","year":"2015"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0081|cit81","volume-title":"The 2015 Annual SHOT Report","author":"Bolton-Maggs","year":"2016"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1537-2995.2010.02873.x","article-title":"Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period","volume":"51","author":"Cazenave","year":"2011","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/tme.12126","article-title":"Where did platelets go in 2012? A survey of platelet transfusion practice in the north of England","volume":"24","author":"Charlton","year":"2014","journal-title":"Transfusion Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009072.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1423-0410.2003.00351.x","article-title":"Preclinical safety profile of plasma prepared using the INTERCEPT Blood System","volume":"85","author":"Ciaravino","year":"2003","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0085|cit85","unstructured":"Veritas Health Innovation Covidence systematic review software 2016"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0086|cit86","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0087|cit87","unstructured":"European Medicines Agency ICH Topic E2A Clinical safety data management: definitions and standards for expedited reporting www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"issue":"5","key":"10.1002\/14651858.CD009072.pub3-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004269.pub3","article-title":"Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation","author":"Estcourt","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009072.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/trf.12058","article-title":"The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions","volume":"53","author":"Estcourt","year":"2013","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/vox.12414","article-title":"Riboflavin and ultraviolet light: impact on dengue virus infectivity","volume":"111","author":"Faddy","year":"2016","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1111\/trf.13778","article-title":"Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study","volume":"56","author":"Fedele","year":"2016","journal-title":"Transfusion"},{"issue":"12","key":"10.1002\/14651858.CD009072.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/trf.13887","article-title":"Blood products use in France: a nationwide cross-sectional survey","volume":"56","author":"Fillet","year":"2016","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(03)12195-2","article-title":"Transfusion medicine: looking to the future","volume":"361","author":"Goodnough","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009072.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.transci.2006.01.007","article-title":"The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends","volume":"35","author":"Goodrich","year":"2006","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V91.6.2180","article-title":"Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA","volume":"91","author":"Grass","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD009072.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1562\/0031-8655(2004)080<0609:TNSIAQ>2.0.CO;2","article-title":"Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology","volume":"80","author":"Hardwick","year":"2004","journal-title":"Photochemistry and Photobiology"},{"issue":"5","key":"10.1002\/14651858.CD009072.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood-2013-09-524348","article-title":"Hepatitis E transmission by transfusion of Intercept blood system-treated plasma","volume":"123","author":"Hauser","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0098|cit98","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0099|cit99","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0100|cit100","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0101|cit101","first-page":"1","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1086\/529143","article-title":"Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets","volume":"46","author":"Jacobs","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000065314","article-title":"Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen hydrochloride and UVA light for pathogen inactivation","volume":"29","author":"Janetzko","year":"2002","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0104|cit104","first-page":"PO34","article-title":"A survey of where and why platelets are used in hospitals in the South West region of England","volume":"23","author":"Jones","year":"2013","journal-title":"Transfusion Medicine"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0105|cit105","first-page":"343","article-title":"A prospective, active haemovigilance study with combined cohort analysis of 19175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment","volume":"109","author":"Knutson","year":"2015","journal-title":"International Journal of Transfusion Medicine"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1562\/2003-12-23-RA-036.1","article-title":"Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level","volume":"80","author":"Kumar","year":"2004","journal-title":"Photochemistry and Photobiology"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/vox.12158","article-title":"Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma","volume":"107","author":"Kwon","year":"2014","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0108|cit108","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD009072.pub3-BIB0109|cit109","first-page":"39","article-title":"Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusion","volume":"25","author":"Lin","year":"1998","journal-title":"Infusion Therapy Transfusion Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009072.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1537-2995.2004.04125.x","article-title":"Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria","volume":"44","author":"Lin","year":"2004","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.0041-1132.2005.04316.x","article-title":"Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light","volume":"45","author":"Lin","year":"2005","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1309\/RAPQ3NXG3MV9AL94","article-title":"Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections","volume":"28","author":"McCullough","year":"2007","journal-title":"American Journal of Clinical Pathology"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jca.20025","article-title":"In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days","volume":"19","author":"Moog","year":"2004","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1537-2995.2008.01643.x","article-title":"A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment","volume":"48","author":"Osselaer","year":"2009","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1537-2995.2009.02151.x","article-title":"Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use","volume":"49","author":"Osselaer","year":"2009","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/trf.12686","article-title":"Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system","volume":"54","author":"Owada","year":"2014","journal-title":"Transfusion"},{"issue":"24","key":"10.1002\/14651858.CD009072.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-3148.2010.01037.x","article-title":"Screening of platelets for bacterial contamination at the Welsh Blood Service","volume":"21","author":"Pearce","year":"2011","journal-title":"Transfusion Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009072.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2005.04.001","article-title":"Pathogen inactivation techniques","volume":"19","author":"Pelletier","year":"2006","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"6","key":"10.1002\/14651858.CD009072.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1537-2995.2005.04350.x","article-title":"Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates","volume":"45","author":"Perez-Pujol","year":"2005","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD009072.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1423-0410.2009.01176.x","article-title":"Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction","volume":"97","author":"Picker","year":"2009","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tmrv.2007.12.003","article-title":"Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation","volume":"22","author":"Reddy","year":"2008","journal-title":"Transfusion Medicine Reviews"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1423-0410.2010.01319.x","article-title":"Pathogen inactivation of platelet concentrates","volume":"99","author":"Reesink","year":"2010","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0124|cit124","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1537-2995.2004.03355.x","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light","volume":"44","author":"Ruane","year":"2004","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0126|cit126","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7","key":"10.1002\/14651858.CD009072.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009072.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.0041-1132.2004.04145.x","article-title":"Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light","volume":"44","author":"Snyder","year":"2004","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0129|cit129","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1-2","key":"10.1002\/14651858.CD009072.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mrgentox.2007.02.008","article-title":"The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment","volume":"630","author":"Tice","year":"2007","journal-title":"Mutation Research"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Tierney JF Stewart LA Ghersi D Burdett S Sydes MR Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 10.1186\/1745-6215-8-16","DOI":"10.1186\/1745-6215-8-16"},{"issue":"23","key":"10.1002\/14651858.CD009072.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1182\/blood-2011-11-393165","article-title":"The impact of platelet transfusion characteristics on post-transfusion platelet increments and clinical bleeding in patients with hypo-proliferative thrombocytopenia","volume":"119","author":"Triulzi","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0133|cit133","unstructured":"US Food Drug Administration What is a serious adverse event? www.accessdata.fda.gov\/scripts\/medwatch\/medwatch-online.htm"},{"issue":"5","key":"10.1002\/14651858.CD009072.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1537-2995.2010.02925.x","article-title":"Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets","volume":"51","author":"Vamvakas","year":"2011","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1423-0410.2000.7940206.x","article-title":"Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats","volume":"79","author":"Rhenen","year":"2000","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0136|cit136","unstructured":"World Bank World Bank country and lending groups: current classification by income datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups (accessed September 2016)"},{"issue":"11","key":"10.1002\/14651858.CD009072.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1537-2995.2012.03634.x","article-title":"A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia","volume":"52","author":"Webert","year":"2012","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0138|cit138","unstructured":"Whitaker BI Hinkins S The 2011 National Blood Collection and Utilization Survey Report www.hhs.gov\/ash\/bloodsafety\/nbcus\/"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0139|cit139","unstructured":"World Health Organization Blood transfusion safety: haemovigilance www.who.int\/bloodsafety\/haemovigilance\/en\/"},{"issue":"2","key":"10.1002\/14651858.CD009072.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tmrv.2011.07.007","article-title":"Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations","volume":"26","author":"Zou","year":"2012","journal-title":"Transfuion Medicine Reviews"},{"key":"10.1002\/14651858.CD009072.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S39-44","DOI":"10.1111\/trf.13330","article-title":"Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period","volume":"56","author":"\u0141\u0119towska","year":"2016","journal-title":"Transfusion"},{"issue":"4","key":"10.1002\/14651858.CD009072.pub3-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","author":"Butler","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009072.pub3-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009072.pub2","article-title":"Pathogen-reduced platelets for the prevention of bleeding","author":"Butler","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009072.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T17:36:54Z","timestamp":1719337014000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009072.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,30]]},"references-count":143,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009072.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727857150.793545724","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,30]]}}}